Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Hematologic Oncology Update · Jul 9, 2026 · 1:57:14

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information and select publications